Howard M. Glase
Chief Executive Officer at Verity Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Neil Fleshner | M | 60 |
Verity Pharmaceuticals, Inc.
 Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON.
POINT Biopharma Corp.
 POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 8 years |
| Joe McCann | M | 47 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 5 years |
| Allan Silber | M | 75 |
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 6 years |
| Jonathan Goodman | M | 56 |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Jay Silber | M | - |
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON. | 5 years |
| Peggy Gilmour | F | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Gerry Hogue | M | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Robert W. Rieder | M | 78 |
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON. | - |
| Margaret Gilmour | F | 64 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Jessica Jensen | F | 44 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Justyna Kelly | F | 39 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
| Gerald Hogue | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| William Demers | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Michael Gottlieb | M | 45 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Ari Shomair | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 13 | 86.67% |
| Canada | 8 | 53.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Howard M. Glase
- Personal Network
